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 ABSTRACT 
 Detection of AmpC-mediated resistance in Gram negative organisms poses a problem due to misleading results in 
phenotypic tests. There are no recommended guidelines for detection of this resistance mechanism and there is a need to 
address this issue as much as the detection of extended spectrum beta lactamases (ESBLs) since both may co-exist and mask 
each other. Several methods have been used to detect the presence of AmpC β-lactamase production in some isolates but 
most of these methods are not reliable. There is a need for a reliable method of evaluating the presence of AmpC β-
lactamases in clinical isolates. A total of 81 consecutive non repetitive clinical isolates of Escherichia coli (n=40) and 
Klebsiella spp. (n=41) were screened for AmpC production by disc diffusion method using cefoxitin (30 µg) disc and 
confirmed by inhibitor based test using boronic acid as inhibitor. A total of 16 E.coli isolates (40%) and 16 Klebsiella 
isolates (39.02%) screened harbored AmpC enzymes, of which 43.75% of E.coli and 56.25% of Klebsiella isolates co-
produced ESBL enzymes. Pure AmpC production was observed in 56.25% of E.coli and 43.75% of Klebsiella isolates. The 
inhibitor based test was useful in identifying cefoxitin susceptible AmpC producers and could also effectively 
differentiate ESBL from AmpC producing isolates. 
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INTRODUCTION 
AmpC β-lactamases have gained importance since 
the late 1970s as one of the mediators of 
antimicrobial resistance in Gram negative bacilli. 
These enzymes are cephalosporinases capable of 
hydrolyzing all β-lactams to some extent (1). AmpC 
β-lactamases are two types – plasmid-mediated and 
chromosomal or inducible AmpC. Chromosomal 
AmpC enzymes are seen in organisms such as 
Citrobacter freundii, Enterobacter cloaca, Morganella 
morganii, Hafnia alvei and Serratia marcescens and are 
typically inducible by β-lactam antibiotics such as 
cefoxitin and imipenem but poorly induced (if at 
all) by the third or fourth generation 
cephalosporins (2). The most common cause  
of AmpC over expression in clinical isolates is a 
mutation in ampD leading to AmpC 
hyperinducibility or constitutive hyperproduction 
(3). 
Plasmid-mediated AmpC β-lactamases have been 
found worldwide but are less common than 
extended-spectrum β-lactamases (ESBLs), and in 
E.coli, they appear to be less often a cause of 
cefoxitin resistance than an increased production of 
chromosomal AmpC β-lactamase (4). Most strains 
with plasmid-mediated AmpC enzymes have been 
isolated from patients after several days of 
hospitalization, but recently, AmpC-producing 
isolates in cultures from long-term care facilities, 
rehabilitation centers, and outpatient clinics have 
been reported (5;6). Risk factors for bloodstream 
infections caused by AmpC-producing strains of 
Klebsiella pneumoniae include long hospital stay, care  
 
 
in an intensive care unit (ICU), central venous 
catheterization, need for an indwelling urinary 
catheter, and prior administration of antibiotics, 
especially broad-spectrum cephalosporins and β-
lactamase inhibitor combinations, and are thus 
similar to risk factors for infection by ESBL-
producing K.pneumoniae strains (7;8).  
For clinical microbiologists, detection of AmpC-
mediated resistance in Gram negative organisms 
poses a problem because the phenotypic tests may 
be misleading resulting in misreporting and 
treatment failures. There are presently no CLSI or 
other approved criteria for AmpC detection (9). 
Organisms producing enough AmpC β-lactamase 
will typically give a positive ESBL screening test 
but fail for the confirmatory test involving 
increased sensitivity with clavulanic acid (10). 
Screening with cefoxitin disc is recommended for 
initial detection. However, it does not reliably 
indicate AmpC production. Some of the phenotypic 
tests include the three-dimensional tests (11), 
double-disk test (12) and Etest strips with gradient 
of cefotetan or cefoxitin on one half and the same 
combined with a constant concentration of 
cloxacillin on the other half (13).   
This study was undertaken to detect the presence 
of AmpC β-lactamases in clinical Gram negative 
isolates by inhibitor based method using boronic 
acid (BA) (14) and also assess if this test could be 
used to differentiate between ESBLs and AmpC 






 MATERIALS AND METHOD  
 A total of 40 E.coli isolates and 41 Klebsiella isolates 
were obtained from clinical samples from Federal 
Medical center, Owerri, Nigeria. Of the 40 E.coli 
isolates, 10 isolates each were obtained from urine 
samples, wound, stool and high vaginal swab 
(HVS). Of the 41 Klebsiella isolates, 16 were obtained 
from urine, 12 from wound while 13 isolates were 
from stool samples. 
 
 ANTIBIOTIC SUSCEPTIBILITY TEST  
 Antibiotic susceptibility testing was performed 
using Kirby Bauer method on Mueller-Hinton agar 
according to CLSI guidelines (15). The antibiotics 
tested (in µg) were cefoxitin (30), ceftazidime (30), 
gentamicin (5), ciprofloxacin (5), ampicillin (10), 
amikacin (30), cefepime (30), cefotaxime (30) and 
imipenem (10). E.coli ATCC 25922 and Klebsiella 
pneumoniae ATCC 700603 were used as control 
strains. 
 
 ESBL SCREENING  
 Isolates were tested for ESBL production using the 
method described previously (16). Briefly, disks 
containing standard 30 µg of aztreonam, 
ceftazidime and cefriaxone were placed 15 mm 
(edge to edge) from an amoxicillin-clavulanic acid 
disk (20 and 10 µg, respectively) on inoculated 
Mueller-Hinton agar. Inoculated media were 
incubated overnight at 35 oC. An enhanced zone of 
inhibition between any one of the β-lactam disks 
and the disk containing clavulanic acid was 
interpreted as evidence for the presence of an ESBL. 
 
 AMP C β-LACTAMASE PRODUCTION TEST  
All isolates were tested for AmpC β-lactamase 
production on disks containing boronic acid (14). A 
disk containing 30 µg of cefoxitin and another 
containing 30 µg of cefoxitin with 400 µg of boronic 
acid were placed on Mueller-Hinton agar. An 
organism demonstrating a zone diameter around 
the disk containing cefoxitin and boronic acid ≥5 
mm than the zone diameter around the disk 




Data obtained from this study were analyzed using 
a two-way analysis of variance (ANOVA) and 




All the isolates were susceptible to at least one of 
the antibiotics. Most of the E.coli isolates were 
susceptible to cefoxitin, gentamicin, ceftazidin, 
ciprofloxacin, cefotaxime and amikacin, while 
majority of them were resistant to imipenem (figure 
1). The Klebsiella species were less susceptible to 
ampicillin, cefepine, imipenem and amikacin but 
the majority were susceptible to cefoxitin, 
ciprofloxacin and cefotaxime. Klebsiella species were 
more susceptible to the antibiotics tested than the 
E.coli isolates.  
 
KEY:  CEFO- cefoxitin, CEFT- ceftazidin,  
GENT- gentamicin, CIPRO- ciprofloxacin 
AMP- ampicillin, CEFE- cefepine, CEFO- cefotaxime 
IMIP- imipenem , AMIK- amikacin                           
                        
It was observed that most of the susceptible isolates 
were from urine samples (58.24% and 48.28% for 
Klebsiella and E.coli, respectively), while the least 
were from stool (17.58%) and HVS (8.62%) samples 
for Klebsiella and E.coli isolates respectively (figures 
2 and 3).The number of Klebsiella isolates got from 
urine samples were more than E.coli isolates. The 
percentage prevalence of susceptible isolates from 
urine samples was significantly higher than those 




AmpC beta lactamase was detected in 16(40%) of 
the E.coli isolates. Of these isolates, 7(43.75%) were 
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Figure 2. percentage source distribution of 







Figure 3. percentage source distribution of 













pure AmpC producers. The percentage prevalence 
of these isolates from urine samples was 
significantly higher than those from other samples 
(p≤0.05). Wound samples had the least percentage 
distribution of the isolates which are pure AmpC 
producers (11.11%) (Figure 4). In each case, the 
number of pure AmpC producers was more than 
those with combined ESBL and AmpC production 
except in the wound sample where the number of 
combined ESBL and AmpC producers was more 
than the pure AmpC producers.  
 
Sixteen (39.02%) out of 41 Klebsiella isolates were 
AmpC producers. Of this number, 9(56.25%) were 
both ESBL and AmpC producers while 7(43.75) 
were pure AmpC producers. Most of these isolates 
were also from urine samples (figure 5).The 
number of isolates with combined ESBL and AmpC 
production were more than the number of pure 
AmpC producers in both urine and wound samples 
but in the stool sample, the number of pure AmpC 
producers was more than those with combined 
ESBL and AmpC production. 
   
DISCUSSION 
Currently, CLSI documents do not indicate the 
screening and confirmatory tests that are optimal 
for detection of AMP C beta lactamases (17). 
However, several studies have been done on 
various test methods namely, the three dimensional 
test (11), modified double disk test (18), AmpC disk 
test (19), inhibitor based method employing 
inhibitors like boronic acids (14), broth 
microdilution method (14) and cefoxitin agar 
method (20). In spite of many phenotypic tests, 
isoelectric focusing (21) and genotypic 
characterization (22) are considered gold standards 
as the results with the phenotypic tests can be 
ambiguous and unreliable. In the present study, 
inhibitor based method with boronic acid was 
employed for AMP C β-lactamase screening. 
A study by Manchanda and Singh, (23) discovered 
that few of their isolates were susceptible to 
cefoxitime, all of the cefoxitin-susceptible isolates 
that harboured an AmpC β-lactamase had MICs of 
cefoxitin <2 mg/L using the broth dilution method. 
Bauernfeind et al. (33) isolated a clinically 
significant strain of K. pneumoniae that harboured a 
novel type of AmpC β-lactamase and that also 
demonstrated a low level of activity against 
cephamycins (cefoxitin MIC 4 mg/L). This is at 
variance with the present study where majority of 
the isolates were found to be susceptible to 
cefoxitime.  In 2002, Barlow and Hall found ampC 
alleles from the chromosomes of two β-lactam-
sensitive C. freundii strains isolated in the 1920s, 
before the clinical use of antibiotics (24). Cefoxitin 
resistance in AmpC non-producers could be due to 
some other resistance mechanism(s). Lack of 
permeation of porins as one of the resistance 
mechanisms has been reported (25). Hernandez-
Alles et al. (26) have demonstrated that interruption 
of a porin gene by insertion sequences is a common 
type of mutation that causes loss of porin 
expression and increased cefoxitin resistance in K. 
pneumoniae. AmpC production in cefoxitin-
susceptible isolates may have a mechanism similar 
to that of ESBLproducing organisms that appear 
susceptible to ceftazidime by the disc diffusion 
method. These data indicate that although 
screening methods that use cefoxitin in 
standardized methods to detect AmpC-harbouring 
isolates are useful, they are not perfect. The results 
in the present study showed that screening should 
include all the clinical isolates showing resistance to 
any of the cephalosporins and/or aztreonam, 
irrespective of their cefoxitin susceptibility status. 
 
AmpC beta lactamase was detected in 16(40%) of 
the E.coli isolates. Of these isolates, 7(43.75%) were 
in combination with ESBL while 9(56.25%) were 
pure AmpC producers. The percentage prevalence 
of these isolates from urine samples was 
significantly higher than those from other samples 
(p≤0.05). Wound samples had the least percentage 
of susceptible isolates (11.11%). Sixteen (39.02%) 
out of 41 Klebsiella isolates were AmpC producers. 
Of this number, 9(56.25%) were both ESBL and 
AmpC producers while 7(43.75) were pure AmpC 
producers. This prevalence was higher when 
compared with the reports from other parts of the 
world (27; 28; 29; 30). 
 
It has been stated that the AmpC beta lactamases 
when present along with ESBLs can mask the 
phenotype of the later (31). In this study, it was 
found that both of these enzymes were equally 
expressed suggesting a possible low level 
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Figure 5. percentage source ditribution of AMPC, ESBL and 
                 AMPC, and pure AMPC producers among Klebsiella 
isolates
AMP C






these AmpC producers, chromosomal derepressed 
and plasmid mediated enzymes were not 
distinguished as this requires genotypic 
confirmatory tests. Sixteen of the forty-one Klebsiella 
isolates screened were AmpC producers suggesting 
the presence of plasmid mediated mechanism as 
these species do not harbor chromosomal AmpC 
genes (31). The susceptibility of ceftazidime and 
cefotaxime serves as a poor marker for the 
identification of AmpC enzymes (14). It is known 
that plasmid mediated AmpC enzymes can 
sometimes appear falsely susceptible to these drugs 
(32). There are newer Ambler class C (ACC) type of 
enzymes which have relatively a lower activity to 
cefoxitin (33) and hence appear susceptible. In the 
present study, some of the AmpC producing 
isolates were susceptible to the third generation 
cephalosporins and cefoxitin by the disc diffusion 
method. This indicates the probable presence of 
such ACC enzymes. This needs to be confirmed by 
molecular methods. 
The inhibitor based confirmatory method appears 
promising for AmpC detection as it increased the 
sensitivity of the test by picking up additional 
AmpC producers. Boronic acid has been reported 
to be effective inhibitor of class C beta lactamases 
(34; 35; 36). In addition, it can also differentiate 
ESBL enzymes from the AmpC enzymes. 
To conclude, a mixed type of drug resistance 
mechanisms seem to operate in the isolates tested. 
There is need for a correct and reliable phenotypic 
test to identify AMP C beta lactamases and ESBL 
producers. Inhibitor based method using boronic 
acid appears to be effective in discriminating this 
type of resistant isolates.          
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